Litigation Details for United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation (D. Mass. 2015)
✉ Email this page to a colleague
United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation (D. Mass. 2015)
| Docket | ⤷ Try a Trial | Date Filed | 2015-06-22 |
| Court | District Court, D. Massachusetts | Date Terminated | 2017-07-06 |
| Cause | 15:2 Antitrust Litigation | Assigned To | Allison Dale Burroughs |
| Jury Demand | Plaintiff | Referred To | |
| Parties | AFSCME HEALTH AND WELFARE FUND | ||
| Patents | 6,894,051; 7,544,799; RE43,799; RE43,932 | ||
| Attorneys | Devona L. Wells | ||
| Firms | Lockridge Grindal Nauen PLLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation (D. Mass. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-06-22 | 1 | application issued as U.S. Patent No. 6,894,051 (“the ’051 patent”). The ’051 patent expires on November 23… U.S. Patent No. 5,521,184 (“the ’184 Patent,” “the Zimmermann Patent,” or “the compound patent”), and…submitted all three patents (the ’184 patent, the ’051 patent, and the ’799 patent) to the FDA for listing…infringe the patent. 63. Patents are not bulletproof. To the contrary, patents are routinely…submit to the FDA the patent number and expiration date on a patent when the patent (1) “claims the drug | External link to document | |
| 2016-04-08 | 106 | ’097 application issued as U.S. Patent No. 6,894,051. The ’051 patent expires on November 23, 2019. … U.S. patent No. 5,521,184 (“the ’184 patent,” the “Zimmermann patent,” or the “compound patent”) and…submitted all three patents (the ’184 patent, the ’051 patent, and the ’799 patent) to the FDA for listing…infringe the patent. b. Patents are Not Bulletproof 65. Patents are not …submit to the FDA the patent number and expiration date on a patent when the patent (i) “claims the drug | External link to document | |
| 2017-06-30 | 140 | 1) U.S. Patent No. 6,894,051 (“the ‘051 Patent”) issued on May 17, 2005, and (2) U.S. Patent No. 7,554,799…submitted all three patents—the original ‘184 Patent, the ‘051 Patent, and the ‘799 Patent—to the FDA to be…assignee of U.S. Patent No. 5,521,184 (“the ‘184 Patent”), which is the basic compound patent claiming Gleevec…of the ‘051 Patent. Plaintiffs allege that the ‘799 Patent was broader than the ‘051 Patent, which claimed…that the ‘051 Patent is invalid. The ‘799 Patent was eventually reissued as the RE’932 Patent. | External link to document | |
| 2018-08-21 | 150 | imatinib mesylate, or Patent No. 6,894,051 ("Patent '051"), on May 17, 2005…the United States Patent and Trademark Office ("Patent Office") a patent for a particular … in enforcing its patent if it obtained that patent through a fraud on the Patent Office, Walker Process…obtained the original patent for Gleevec, or Patent No. 5,521,184 ("Patent '184"). …corresponding patents -- as one of the patents, along with the as-yet-unexpired original '184 patent, that | External link to document | |
| 2015-07-24 | 51 | U.S. Patent 6,894,051 (the “’051 Patent”) and U.S. Reissue Patent RE43,932 (the “RE932 Patent”) (collectively… 2019. The RE932 Patent is a “reissue” of U.S. Patent No. 7,544,799 (the “’799 Patent”), which is also…Polymorph Patents, as well as NPC’s legitimate efforts to enforce those patents. The Polymorph Patents have… prosecuting patent litigation against generic manufacturer Sun on the basis of a patent that it knew…outstanding patent that Plaintiffs claim was invalid. To establish that claim, and overcome a patent owner’ | External link to document | |
| 2015-07-29 | 54 | Gleevec® – U.S. Patent No. 6,894,051 (“’051 patent”), issued on May 17, 2005, and U.S. Patent No. 7,544,799…compound patent covering the active ingredient, imatinib, U.S. Patent No. 5,521,184 (the “’184 patent”) issued…i) the Patent Office Board of Appeals determined that the Polymorph Patents claimed patentable subject…arguments before the patent examiner, neither the ’051 patent nor the ’799/RE932 patent, would have issued…enforcement of a patent obtained by fraud on the Patent Office could subject the patent holder to antitrust | External link to document | |
| 2015-08-31 | 69 | here – is that Novartis’ U.S. Patent No. 6,894,051 (the “’051 patent”) is invalid. Absent such a finding…assertion that the patent owner settled to avoid patent invalidation; and any patent, regardless of taint…Plaintiffs allege, the ’051 patent is so flawed that victory was assured in the patent lawsuit filed by Sun …’051 patent simply based on their argument that the settlement prevented a ruling on the patent’s validity…conclusory allegation that the patent holder engaged in a “scheme” to avoid patent invalidation merely by settling | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
